BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

373 related articles for article (PubMed ID: 19144399)

  • 1. Eculizumab for paroxysmal nocturnal haemoglobinuria.
    Parker C
    Lancet; 2009 Feb; 373(9665):759-67. PubMed ID: 19144399
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Effect of eculizumab on hemolysis and transfusion requirements in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Hall C; Marsh JC; Elebute M; Bombara MP; Petro BE; Cullen MJ; Richards SJ; Rollins SA; Mojcik CF; Rother RP
    N Engl J Med; 2004 Feb; 350(6):552-9. PubMed ID: 14762182
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Eculizumab, a terminal complement inhibitor, improves anaemia in patients with paroxysmal nocturnal haemoglobinuria.
    Schubert J; Hillmen P; Röth A; Young NS; Elebute MO; Szer J; Gianfaldoni G; Socié G; Browne P; Geller R; Rother RP; Muus P;
    Br J Haematol; 2008 Jun; 142(2):263-72. PubMed ID: 18503589
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Eculizumab: A novel therapy for paroxysmal nocturnal hemoglobinuria.
    Zareba KM
    Drugs Today (Barc); 2007 Aug; 43(8):539-46. PubMed ID: 17925885
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Treatment of paroxysmal nocturnal hemoglobinuria in the era of eculizumab.
    Röth A; Dührsen U
    Eur J Haematol; 2011 Dec; 87(6):473-9. PubMed ID: 21883481
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Paroxysmal nocturnal hemoglobinuria and the complement system: recent insights and novel anticomplement strategies.
    Risitano AM
    Adv Exp Med Biol; 2013; 735():155-72. PubMed ID: 23402025
    [TBL] [Abstract][Full Text] [Related]  

  • 7. The complement inhibitor eculizumab in paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Young NS; Schubert J; Brodsky RA; Socié G; Muus P; Röth A; Szer J; Elebute MO; Nakamura R; Browne P; Risitano AM; Hill A; Schrezenmeier H; Fu CL; Maciejewski J; Rollins SA; Mojcik CF; Rother RP; Luzzatto L
    N Engl J Med; 2006 Sep; 355(12):1233-43. PubMed ID: 16990386
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Discovery and development of the complement inhibitor eculizumab for the treatment of paroxysmal nocturnal hemoglobinuria.
    Rother RP; Rollins SA; Mojcik CF; Brodsky RA; Bell L
    Nat Biotechnol; 2007 Nov; 25(11):1256-64. PubMed ID: 17989688
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Eculizumab opens a new era of treatment for paroxysmal nocturnal hemoglobinuria.
    Schrezenmeier H; Höchsmann B
    Expert Rev Hematol; 2009 Feb; 2(1):7-16. PubMed ID: 21082989
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Eculizumab in paroxysmal nocturnal haemoglobinuria.
    Charneski L; Patel PN
    Drugs; 2008; 68(10):1341-6. PubMed ID: 18578555
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Clinical roundtable monograph: Paroxysmal nocturnal hemoglobinuria: a case-based discussion.
    Szer J; Hill A; Weitz IC
    Clin Adv Hematol Oncol; 2012 Nov; 10(11 Suppl 21):1-16. PubMed ID: 23271156
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Achievements and limitations of complement inhibition by eculizumab in paroxysmal nocturnal hemoglobinuria: the role of complement component 3.
    Risitano AM; Perna F; Selleri C
    Mini Rev Med Chem; 2011 Jun; 11(6):528-35. PubMed ID: 21561403
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Learnings from over 25 years of PNH experience: the era of targeted complement inhibition.
    Heitlinger E
    Blood Rev; 2013 Dec; 27 Suppl 1():S1-6. PubMed ID: 24331206
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effect of eculizumab on haemolysis-associated nitric oxide depletion, dyspnoea, and measures of pulmonary hypertension in patients with paroxysmal nocturnal haemoglobinuria.
    Hill A; Rother RP; Wang X; Morris SM; Quinn-Senger K; Kelly R; Richards SJ; Bessler M; Bell L; Hillmen P; Gladwin MT
    Br J Haematol; 2010 May; 149(3):414-25. PubMed ID: 20230403
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Eculizumab: a review of its use in paroxysmal nocturnal haemoglobinuria.
    McKeage K
    Drugs; 2011 Dec; 71(17):2327-45. PubMed ID: 22085388
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Long-term effect of the complement inhibitor eculizumab on kidney function in patients with paroxysmal nocturnal hemoglobinuria.
    Hillmen P; Elebute M; Kelly R; Urbano-Ispizua A; Hill A; Rother RP; Khursigara G; Fu CL; Omine M; Browne P; Rosse W
    Am J Hematol; 2010 Aug; 85(8):553-9. PubMed ID: 20658586
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Eculizumab: a guide to its use in paroxysmal nocturnal hemoglobinuria.
    Keating GM; Lyseng-Williamson KA; McKeage K
    BioDrugs; 2012 Apr; 26(2):125-30. PubMed ID: 22350448
    [TBL] [Abstract][Full Text] [Related]  

  • 18. [Paroxysmal nocturnal hemoglobinuria and thrombosis in the era of eculizumab].
    Nishimura JI
    Rinsho Ketsueki; 2018; 59(8):1042-1047. PubMed ID: 30185704
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Recent developments in the understanding and management of paroxysmal nocturnal haemoglobinuria.
    Hill A; Richards SJ; Hillmen P
    Br J Haematol; 2007 May; 137(3):181-92. PubMed ID: 17408457
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Pegcetacoplan: A Review in Paroxysmal Nocturnal Haemoglobinuria.
    Heo YA
    Drugs; 2022 Dec; 82(18):1727-1735. PubMed ID: 36459381
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 19.